Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
about
Acute decompensated heart failure: contemporary medical managementVasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data.Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Diuretic use in heart failure and outcomes.Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.Arginine vasopressin receptor signaling and functional outcomes in heart failureAssociation of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialEnhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats.The current and future management of acute heart failure syndromes.Vasopressin-receptor antagonists.Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).Chronic heart failure: current evidence, challenges to therapy, and future directions.Novel therapeutic targets for the treatment of heart failure.Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.Hyponatremia: an update on current pharmacotherapy.Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials.Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists?Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failureTolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.
P2860
Q24650932-4DFB8C16-FBFA-4517-8880-9726E0918E60Q30717243-8DBBE30B-A136-40AB-9E81-CC63A6F52E02Q34241396-2B20C96A-A7BD-4271-87E1-F3690D167DC9Q34357452-A76C8251-03A8-4B56-A9BF-0B294E1DF7F9Q35164124-F25881AB-997C-45D8-A591-4AF3C5E9F653Q36329310-E45D4199-208A-4CF6-BD61-B0FEEFB81E83Q37149761-5301396C-EA49-4398-BC2D-1A02BF2CFACBQ37214187-4E8A91C7-D73E-489C-8012-8A7F7D24D962Q37323514-04AF40AF-D0B1-40A5-B419-9222A73A01BEQ37703984-E4D44E2B-C53E-46DC-AB0F-69270AB0824DQ37770574-7220BE9C-F85E-4DD5-801A-0EAB7D13A082Q37843827-E1C6C62D-4353-4F36-A772-2303BDC09FB6Q37880858-59D507E5-83BE-472A-8C98-BC75D981C707Q37893956-E1ADC01E-9B3C-4A62-B8D2-B8E112E3B20AQ37923340-3A323ECB-E5AE-4E07-8C05-D6175E97715DQ38089919-8B72BCD2-850E-48C8-90B3-D6E34606B1B2Q38256581-19E2C16F-25D6-44E1-BE97-2233FED45572Q38962878-EAD44D6B-39B3-4A93-9893-1938CAEE0522Q39456742-275CB8F1-AB67-49FE-95D0-157BAE83AC26Q39660099-ED5B20B4-4B15-47FF-A369-149437DE0EAEQ40508135-4BCC6467-1D9E-4D58-8710-A7ECEB2E655FQ42723611-18B3F7C8-3A32-4B49-96A6-374CDDC97E11Q51564442-2DA0EBE4-3554-4873-9CB9-5B604CC20D43
P2860
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@en
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@nl
type
label
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@en
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@nl
prefLabel
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@en
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@nl
P2093
P1433
P1476
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
@en
P2093
James E Udelson
John J Finley
Marvin A Konstam
P304
P356
10.1161/CIRCULATIONAHA.108.765289
P407
P577
2008-07-01T00:00:00Z